Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093652 · ClinicalTrials.gov registry record · Phase 1
Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00093652 is a Phase 1 study that was terminated before completion, run by Roswell Park Cancer Institute.
The verdict
NCT00093652, a Phase 1 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining oxaliplatin and gefitinib with radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of oxaliplatin when given together with gefitinib and radiation therapy and to see how well they work in treating patients with locally advanced or metastatic esophageal cancer.
Interventions
- DRUG oxaliplatin
- PROCEDURE conventional surgery
- RADIATION radiation therapy
- DRUG gefitinib
- PROCEDURE neoadjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00093652
The ClinicalTrials.gov registry entry for NCT00093652 describes a study currently listed as terminated, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which oxaliplatin is the first listed.
NCT00093652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00093652 about?
NCT00093652 is a clinical study titled "Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer". RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to damage tumor...
What is the current status of trial NCT00093652?
This trial is currently terminated. It is a Phase 1 study. The study started on 2003-05.
What interventions are being tested in trial NCT00093652?
The interventions under investigation include: oxaliplatin (DRUG), conventional surgery (PROCEDURE), radiation therapy (RADIATION), gefitinib (DRUG), neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00093652?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.